跳至主要内容
临床试验/NCT01901289
NCT01901289已完成不适用

Zilver® PTX® Drug-Eluting Peripheral Stent Post-Approval Study

Cook Research Incorporated32 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2013年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
200
试验地点
32
主要终点
Patients Without Target Lesion Revascularization (TLR)

研究概览

简要总结

The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient has signed and dated the informed consent.
  • Patient has symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
  • Patient agrees to return for the required follow-up assessments.

排除标准

  • Patient is < 18 years of age.
  • Patient has significant stenosis of inflow tract not successfully treated before this procedure.
  • Patient lacks at least one patent vessel of runoff with < 50% stenosis throughout its course.

结局指标

主要结局

Patients Without Target Lesion Revascularization (TLR)

时间窗: 1 year

A reintervention performed for ≥ 50 % diameter stenosis within ± 5 mm proximal and /or distal to the target lesion after documentation of recurrent clinical symptoms of peripheral arterial disease (PAD) following the initial procedure.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (32)

Loading locations...

相似试验